Last reviewed 2026-04-19 · How we verify

HA antigens

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults (PHASE1)
• High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
• High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
• Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age (PHASE3)
• High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
• A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months (PHASE3)
• High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (PHASE2)
• A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.